Development of a T Cell Engineering Platform for Fully-Individualized Neoantigen-Specific TCR-Based Immunotherapy

Join this 35-minute webinar presented by Dr. Xiangjun Kong, Principal Scientist at Neogene Therapeutics, who explores the development of a T cell engineering platform for fully-individualized neoantigen-specific TCR therapy. Learn about this promising new immunotherapy approach involving adoptive transfer of T cell receptor (TCR)-edited T cells to target cancer neoantigens. Discover how the platform identifies neoantigen-reactive TCRs in a high-throughput and patient-specific manner, potentially advancing personalized cancer treatment strategies. Dr. Kong brings extensive research experience in high-throughput functional screening and genome editing technologies to this informative presentation hosted by Labroots.